Tulane University AIDS Clinical Trials Unit
Pharmaceutical Industry-Sponsored Protocols
Open for Enrollment
Contents
Fungal Studies (by organism)
Anti-Retroviral Drugs
Contacting the Study Nurse
Karen Craig, R.N.
Coordinating Investigators for the Tulane Pharmaceutical ACTU Program
Pfizer Central Research 150-602
Efficacy, safety and toleration of Voriconazole versus Amphotericin B in the treatment of acute
invasive aspergillosis in the immunocompromised patient.
Summary of Study
Pfizer Central Research 150-608
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole versus
Conventional Amphotericin B Followed by Fluconazole in the Treatment of Candidemia
in Non Neutropenic Subjects.
Summary of Study Microsoft Word
GlaxoWellcome EPV 20001
A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy
of Indinavir Sulfate 800mg b.i.d. in Combination with Ritonavir 100mg/d4T/3TC b.i.d.
in HIV-Infected Individuals.
Summary of Study Microsoft Word
Merck & Co. 107-00
A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate
300 mg b.i.d. in Combiniation with Ritonavir 200 mg b.i.d. in HIV-1 Infected Individuals Who
Require Early Intervention.
Summary of Study Microsoft Word
ALL STUDY MEDICATIONS AND LAB EVALUATIONS ARE PROVIDED FREE OF
CHARGE!
For more information
and appointment times, call the Tulane-LSU ACTU Pharmaceutical Division Research Nurse:
Karen Craig,
R.N., M.S.N. at (504) 584-3608
Hot Links
Tulane/LSU AIDS Clinical Trials
Unit (ACTU)
Tulane University Section of
Infectious Diseases
Tulane University School of Medicine
If you have comments or suggestions, send email to
kcraig@tulane.edu
Last updated: May 29, 2000